(Q34916352)

5 August 2017

Hypertension as a biomarker of efficacy in patients with metastatic renal cell carcinoma treated with sunitinib (English)

1 reference

metastatic renal cell carcinoma

5 August 2017

0 references

1 reference

1 reference

1 reference

1 reference

9

Robert J Motzer

1 reference

5 August 2017

Brian I Rini

1

1 reference

5 August 2017

Darrel P Cohen

2

1 reference

5 August 2017

Dongrui R Lu

3

1 reference

5 August 2017

Isan Chen

4

1 reference

5 August 2017

Subramanian Hariharan

5

1 reference

5 August 2017

Martin E Gore

6

1 reference

5 August 2017

Robert A Figlin

7

1 reference

5 August 2017

Michael S Baum

8

1 reference

5 August 2017

language of work or name

English

0 references

publication date

28 April 2011

1 reference

Journal of the National Cancer Institute

5 August 2017

1 reference

5 August 2017

103

1 reference

5 August 2017

763-773

1 reference

5 August 2017

9

1 reference

Initial assessment, surveillance, and management of blood pressure in patients receiving vascular endothelial growth factor signaling pathway inhibitors

5 August 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3086879

Clinical course of advanced non-small-cell lung cancer patients experiencing hypertension during treatment with bevacizumab in combination with carboplatin and paclitaxel on ECOG 4599.

8 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3086879

Reduction in skin microvascular density and changes in vessel morphology in patients treated with sunitinib

8 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3086879

Relationship between exposure to sunitinib and efficacy and tolerability endpoints in patients with cancer: results of a pharmacokinetic/pharmacodynamic meta-analysis.

8 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3086879

Prognostic factors for overall survival in patients with metastatic renal cell carcinoma treated with vascular endothelial growth factor-targeted agents: results from a large, multicenter study

8 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3086879

Rapid development of hypertension by sorafenib: toxicity or target?

8 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3086879

Safety and efficacy of sunitinib for metastatic renal-cell carcinoma: an expanded-access trial

8 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3086879

Overall survival and updated results for sunitinib compared with interferon alfa in patients with metastatic renal cell carcinoma

8 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3086879

Biomarkers of response and resistance to antiangiogenic therapy

8 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3086879

Risk of hypertension and renal dysfunction with an angiogenesis inhibitor sunitinib: systematic review and meta-analysis

8 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3086879

The molecular basis of class side effects due to treatment with inhibitors of the VEGF/VEGFR pathway

8 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3086879

Hypertension and rarefaction during treatment with telatinib, a small molecule angiogenesis inhibitor

8 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3086879

Sunitinib versus interferon alfa in metastatic renal-cell carcinoma

8 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3086879

Sunitinib in patients with metastatic renal cell carcinoma

8 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3086879

Activity of SU11248, a multitargeted inhibitor of vascular endothelial growth factor receptor and platelet-derived growth factor receptor, in patients with metastatic renal cell carcinoma

8 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3086879

Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure

8 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3086879

New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada

8 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3086879

Hypertension and proteinuria: a class-effect of antiangiogenic therapies.

8 July 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJR128

Vascular endothelial growth factor-induced nitric oxide- and PGI2-dependent relaxation in human internal mammary arteries: a comparative study with KDR and Flt-1 selective mutants

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJR128

Angiogenesis factors and preeclampsia

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJR128

Hypertension and clinical benefit of bevacizumab in the treatment of advanced renal cell carcinoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJR128

Arterial hypertension correlates with clinical outcome in colorectal cancer patients treated with first-line bevacizumab

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJR128

Interferon-alfa as a comparative treatment for clinical trials of new therapies against advanced renal cell carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJR128

Effective strategies for management of hypertension after vascular endothelial growth factor signaling inhibition therapy: results from a phase II randomized, factorial, double-blind study of Cediranib in patients with advanced solid tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJR128

Diagnosis and management of hypertension in advanced renal cell carcinoma: prospective evaluation of an algorithm in patients treated with sunitinib.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJR128

Evolution of renal function in patients treated with antiangiogenics after nephrectomy for renal cell carcinoma

21 January 2018

1 reference

12 December 2020

Effects of vascular endothelial growth factor on hemodynamics and cardiac performance

1 reference

12 December 2020

VEGF upregulates ecNOS message, protein, and NO production in human endothelial cells

1 reference

12 December 2020

Hypertension as a predictive factor of Sunitinib activity

1 reference

12 December 2020

Hypertension, proteinuria, and antagonism of vascular endothelial growth factor signaling: clinical toxicity, therapeutic target, or novel biomarker?

1 reference

12 December 2020

Identifiers

DOI

10.1093/JNCI/DJR128

1 reference

5 August 2017

1 reference

5 August 2017

1 reference